Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanger Institute Spin-Out Microbiotica To Evaluate Bacterial Mixes

Executive Summary

The UK Wellcome Trust Sanger Institute’s latest spin-out has received start-up funding to exploit more than six years of gut bacterial genome sequencing in order to develop novel bacteria-based therapies for a range of diseases.


Related Content

Microbiotica: Wellcome Spin-Out Exploits Unique Microbe Collection
Cambridge Cluster Investor Raises £75m To Fund UK Startups
Seventure Partners Fund Focuses On Microbiome Revolution
Shaping Microbiome R&D's Future: Is Big Pharma Missing The Boat?
Synlogic Links Up With AbbVie For IBD Microbiome Therapies
Venture Funding Deals, June 2015
Crescendo Biologics Raises $28M To Develop Fully Human Antibody-Fragment Technology


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts